InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor [2] - InflaRx's lead program is izicopan (INF904), an orally administered small molecule inhibitor that has shown promising pharmacokinetic and pharmacodynamic characteristics in clinical studies [2] Product Development - Izicopan is being developed for the treatment of various inflammatory diseases, including hidradenitis suppurativa [2] - The company has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has demonstrated clinical activity and tolerability in multiple studies [2] Corporate Information - InflaRx was founded in 2007 and has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [3] - InflaRx GmbH and InflaRx Pharmaceuticals Inc. are wholly owned subsidiaries of InflaRx N.V. [3] Upcoming Events - InflaRx will participate in the Raymond James 2026 Biotech Innovation Symposium on April 14, 2026, in New York, NY, where the company will hold one-on-one investor meetings [1]